tradingkey.logo

輝瑞

PFE
查看詳細走勢圖
27.220USD
+0.720+2.72%
收盤 02/06, 16:00美東報價延遲15分鐘
154.77B總市值
19.91本益比TTM

輝瑞

27.220
+0.720+2.72%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+2.72%

5天

+2.95%

1月

+7.04%

6月

+13.75%

今年開始到現在

+9.32%

1年

+5.38%

查看詳細走勢圖

TradingKey 輝瑞股票評分

單位: USD 更新時間: 2026-02-06

操作建議

輝瑞當前公司基本面數據相對健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在藥品行業排名47/159位。機構持股佔比非常高,近一月多位分析師給出公司評級為持有。最高目標價為28.93。中期看,股價處於上升通道。近一個月,市場表現較強,技術面和基本面綜合得分較高,較強的走勢獲得基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

輝瑞評分

相關信息

行業排名
47 / 159
全市場排名
127 / 4521
所屬行業
藥品

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
看空

輝瑞亮點

亮點風險
Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入62.58B美元
高分紅
公司屬於高分紅公司,最新股息支付率119.41%
穩定分紅
公司5年內持續分紅,最新股息支付率119.41%
估值高估
公司最新PE估值19.91,處於3年歷史高位
機構減倉
最新機構持股3.86B股,環比減少2.05%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉,最新持倉110.69K股

分析師目標

基於 29 分析師
持有
評級
28.930
目標均價
+9.21%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

輝瑞簡介

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.
公司代碼PFE
公司輝瑞
CEOBourla (Albert)
網址https://www.pfizer.com/
KeyAI